BRIEF-AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies

July 10 (Reuters) - AB Science SA ABS.PA:

  • AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS

  • AB SCIENCE - DISCONTINUES PHASE 2 STUDY AB20006, PHASE 3 STUDY AB15003, PHASE 3 STUDY AB20009

  • AB SCIENCE - TO SEEK AUTHORIZATION TO INITIATE PHASE 4 OF AB8939, VENETOCLAX, AND AZACITIDINE COMBINATION

  • AB SCIENCE SA: DISCONTINUATION OF STUDIES IS NOT RELATED TO ANY SAFETY CONCERNS REGARDING MASITINIB

  • AB SCIENCE - TO UPDATE PROTOCOL AND SEEK AUTHORIZATION TO RESUME PHASE 3 MASITINIB STUDY IN ALS

Source text: ID:nGNX2NMZ3R

Further company coverage: ABS.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.